|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.660 NZD | 0.00% |
|
-1.61% | +8.28% |
| 06-24 | NZX Biggest Gainers | MT |
| 06-24 | AFT Pharmaceuticals Gets US FDA Nod for Phase 3 Trial of Injectable Iron Therapy | MT |
| Market Cap | 384M 218M 191M 176M 164M 309M 20.72B 316M 2.12B 821M 10.17B 818M 800M 35.39B | P/E 2027 * |
19.5x | P/E 2028 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise Value | 414M 235M 206M 190M 177M 334M 22.33B 340M 2.28B 884M 10.96B 882M 863M 38.14B | EV / Sales 2027 * |
1.36x | EV / Sales 2028 * | 1.18x |
| Free-Float |
22.37% | Yield 2027 * |
0.9% | Yield 2028 * | 1.14% |
Last Transcript: AFT Pharmaceuticals Limited
| 20/01/24 | Rentevrees zet Bel20 onder druk | |
| 19/01/24 | KBC uitblinker op groene beurs | |
| 19/01/24 | Brusselse beurs opent flink hoger | |
| 19/01/24 | Brussel start handelsdag vermoedelijk in het groen | |
| 18/01/24 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 week | -1.61% | ||
| 1 month | -6.87% | ||
| 3 months | +8.93% | ||
| 6 months | +8.28% | ||
| Current year | +8.28% |
| 1 week | 3.66 |  | 3.76 |
| 1 month | 3.65 | | 3.98 |
| Current year | 3.35 | | 3.98 |
| 1 year | 2.54 | | 3.98 |
| 3 years | 2.37 | | 3.98 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 04/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 04/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 15/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Theodore Witek
BRD | Director/Board Member | 69 | 23/12/2020 |
David Flacks
CHM | Chairman | - | 22/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 04/09/1997 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03/07/25 | Buy | Founder | 200,000 | 0.1907% | ||
| 26/06/25 | Free | Founder | 17,755 | 0.0169% | ||
| 02/12/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -1.61% | +32.13% | +1.67% | 218M | |
| -0.64% | +6.67% | +53.59% | +158.28% | 1,070B | |
| +0.00% | +5.39% | +62.89% | +55.48% | 611B | |
| -0.23% | +6.88% | +32.14% | +85.96% | 445B | |
| -3.05% | +4.18% | +31.11% | +23.88% | 329B | |
| -1.74% | +1.94% | +36.90% | +22.86% | 290B | |
| -1.25% | +1.28% | +29.98% | +38.89% | 287B | |
| +2.99% | +5.28% | -26.30% | -41.06% | 213B | |
| -0.22% | +2.82% | +24.37% | +60.58% | 195B | |
| -0.29% | +0.65% | +12.75% | +64.21% | 157B | |
| Average | -0.51% | +4.51% | +28.96% | +47.07% | 359.65B | |
| Weighted average by Cap. | -0.60% | +6.67% | +39.14% | +77.92% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 173M 151M 139M 130M 245M 16.4B 250M 1.68B 650M 8.05B 648M 634M 28.02B | 345M 196M 172M 158M 148M 278M 18.64B 284M 1.91B 738M 9.15B 736M 720M 31.84B |
| Net income | 19.71M 11.19M 9.82M 9.04M 8.43M 15.89M 1.06B 16.21M 109M 42.14M 522M 42.01M 41.1M 1.82B | 24.84M 14.1M 12.38M 11.4M 10.62M 20.03M 1.34B 20.43M 137M 53.1M 658M 52.94M 51.8M 2.29B |
| Net Debt | 29.84M 16.94M 14.87M 13.69M 12.76M 24.06M 1.61B 24.55M 165M 63.8M 791M 63.6M 62.23M 2.75B | 24.59M 13.96M 12.26M 11.28M 10.51M 19.82M 1.33B 20.23M 136M 52.57M 651M 52.41M 51.28M 2.27B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/07/26 | NZ$3.660 | 0.00% | 441 |
| 30/06/26 | NZ$3.660 | -1.08% | 8,406 |
| 29/06/26 | NZ$3.700 | +0.54% | 2,167 |
| 26/06/26 | NZ$3.680 | +0.27% | 7,997 |
| 25/06/26 | NZ$3.670 | -2.13% | 12,778 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
